Fennec Pharmaceuticals Q2 sales rise on PEDMARK demand

Fennec Pharmaceuticals

11/08/2026 12:10

Overview
US specialty pharma's Q2 net product sales rose 78% yr/yr, driven by PEDMARK demand
Non-GAAP adjusted EBITDA for Q2 turned positive from a loss in prior year
Company attributes sales growth to commercial expansion and new PEDMARK accounts

Outlook
Company expects cash and projected PEDMARK revenues to fund operations based on current plan
Fennec Pharmaceuticals sees continued commercial momentum for PEDMARK into third quarter
Company expects sales organization expansion to support further commercial growth

Result Drivers
COMMERCIAL EXPANSION - Co said expansion of commercial organization and increased engagement with healthcare providers drove unprecedented PEDMARK enrollment and sales growth
NEW PEDMARK ACCOUNTS - Co attributed sales growth to increased demand from new accounts, especially in the AYA population

Company press release: ID:nGNX6SB5Ft

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
 
$17.16 mln
 
Q2 Net Income
 
$1.97 mln
 
Q2 Operating Expenses
 
$16.14 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc. is $16.00, about 46.3% above its August 10 closing price of $10.94
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads
Aug 10 - Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
Aug 10 - Axsome Therapeutics Q2 revenue rises on AUVELITY  growth
Aug 10 - Tonix Q2 revenue rises sharply on TONMYA launch

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)